Background: There is an ongoing debate regarding possible cost and benefits, but also harm of universal screening for the emerging sexually transmitted pathogen Mycoplasma genitalium. Methods: From the initial pool of 8665 samples that were tested, a subset of Chlamydia trachomatis-positive and randomly selected C. trachomatis-negative cervical swabs were further interrogated for M. genitalium by real-time polymerase chain reaction, using a 224 bp long fragment of the glyceraldehyde-3-phosphate dehydrogenase gene. Results: M. genitalium was detected in 4.8% of C. trachomatis-positive samples and none of C. trachomatis-negative samples. Accordingly, a significant association was shown between M. genitalium and C. trachomatis (P < 0.01), but also between M. genitalium and Mycoplasma hominis infection (P < 0.01). Conclusions: Based on the results, routine screening is recommended only for women with one or more identified risk factors. Moreover, younger age does not represent an appropriate inclusion/exclusion criterion for M. genitalium testing in the low-risk female population.
Introduction
Mycoplasma genitalium represents an emerging cause of sexually transmitted infections (STIs). [1] It is considered as an independent risk factor for cervicitis in women, but its role in pelvic inflammatory disease, spontaneous abortion and infertility has not been ascertained until recently. [2, 3] The prevalence of M. genitalium in women ranges from <1% to 42%, [4, 5] depending on whether we consider low-risk population (i.e., attendees of general practitioners and public health services) or high-risk population (i.e., sexually transmitted disease clinics attendees or those with specific symptoms).
There is an ongoing debate regarding possible cost and benefits, but also harm of universal screening for M. genitalium among low-risk individuals. Similar to many other countries, M. genitalium infection is not routinely screened for in Croatia and the data of its prevalence in the country are scarce -especially for the female population. Only one study regarding M. genitalium prevalence in Croatia was published thus far, conducted in men attending fertility clinic. [5] The aim of our study was therefore to determine the prevalence of M. genitalium in cervical swabs admitted to the public health laboratory, as well as to detect co-infection patterns of M. genitalium with Chlamydia trachomatis and other STIs in order to assess the necessity of implementing M. genitalium screening in the low-risk female population.
Assessing the

Methods
Swabs were taken from women with a low-risk for STIs, i.e., asymptomatic attendees of primary care gynecologist searching for screening and prenatal care. An unlinked anonymized method to test routinely collected and stored cervical swabs was used. The samples were collected at primary care and private gynecology offices in the Zagreb region, Croatia, and referred to the public health laboratory for routine C. trachomatis and genital Mycoplasma testing. Uniformity of samples collection was maintained Table 1 ]. The mean age of investigated women was 30.9 ± 9.9 years (age range: 1-69); women infected with tested bacteria (with the exception of those infected with M. genitalium) were significantly younger when compared to the uninfected women [ Table 2 ].
Discussion
Such low prevalence of M. genitalium on selected sample of low-risk female population tested for C. trachomatis is comparable to other published studies also conducted on cervical swabs tested for C. trachomatis. [6] However, it seems that the true prevalence of M. genitalium in Croatian low-risk female population is substantially lower, since our study has found M. genitalium only in C. trachomatis positive samples. This presumptive, very low prevalence of M. genitalium infection in low-risk population of women in Croatia is concordant with reported prevalence of 0.8% in French women attending routine screening, [7] but also with previous report of unusually low prevalence of M. genitalium detected in Croatian infertile men and their asymptomatic controls (1.4% and 0%, respectively). [5] Present study also revealed that 4.8% of women with C. trachomatis and 11% of women with M. hominis also had M. genitalium infection, which is lower when compared to 9% of C. trachomatis-M. genitalium co-infected women that underwent population-based screening in London [8] and 11% in a screening study conducted in Norway. [9] The recommended treatment of uncomplicated C. trachomatis and M. genitalium infection is the same, but unlike C. trachomatis that does not show any homotypic resistance, [10] M. genitalium has a high potential for developing resistance. [1] This is the reason why the treatment of cervicitis or nongonoccocal urethritis should be based upon specific diagnostic testing, and a control PCR should be pursued 4-5 weeks after treatment. [11] Moreover, since the therapy for C. trachomatis may not be effective for M. genitalium, the latter pathogen may represent a "Trojan horse" and hamper successful treatment, which is why it is significant to screen for co-infection.
At the moment, the decision to screen or not to screen is usually based on the discussion between health providers and patients (taking into account personal risk factors), especially aiming to test symptomatic women if molecular methods are available. [1] Although recent meta-analysis has shown that testing high-risk symptomatic women on M. genitalium is warranted, [3] our study suggest that in low-risk population it would be reasonable to implement M. genitalium screening only for those with proven risk factor such as C. trachomatis and/or M. hominis infection. Of course, acquiring precise insights into local M. genitalium epidemiology and tracking antimicrobial resistance development may represent a rationale to undertake screening endeavors regardless of the low prevalence of infection.
Conclusions
Other risk factors (i.e., multiple sexual partners, bacterial vaginosis, being symptomatic, smoking, prior miscarriage, black ethnicity, social class, marital status) including younger age are also associated with M. genitalium infection in the literature. [12] Still, although this study demonstrated that women infected with M. genitalium were younger than woman without the infection, this was not statistically significant-hence younger age would not be an appropriate inclusion/exclusion criterion for M. genitalium screening in the low-risk population. In any case, further studies are needed to confirm or reject results of our investigation, especially those trying to elucidate the relationship between younger age and M. genitalium infection.
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